Businesses that manufacture, import, distribute, or sell regulated products in the Philippines may need to secure product authorization from the Food and Drug Administration (FDA) before placing those products on the market. For products covered by the FDA’s Certificate of Product Registration (CPR) system, obtaining an FDA Certificate of Product Registration is an important part of establishing legal and compliant operations.
A CPR is different from an FDA License to Operate (LTO). The LTO generally concerns the establishment and its regulated activities, while the CPR concerns the particular product. A business may therefore need to address both establishment licensing and product registration before commercial distribution.
The specific authorization also depends on the product category. The FDA’s current eServices system provides CPR applications for products including drugs, food, and certain other regulated products. Medical devices and cosmetics, however, have their own authorization systems. For example, Class A medical devices use a Certificate of Medical Device Notification (CMDN), while Class B, C, and D medical devices generally require a Certificate of Medical Device Registration (CMDR). Cosmetics use the notification system rather than the standard CPR process.
The FDA Certificate of Product Registration is a product-level authorization issued for regulated products that fall under a CPR registration framework.
The CPR demonstrates that the FDA has reviewed the product application under the requirements applicable to its product category. For pharmaceutical products, Philippine law requires applicable products to secure FDA authorization before activities such as manufacture, importation, distribution, sale, promotion, or other regulated activities. The FDA describes a CPR or marketing authorization as evidence of marketing authority for the registered health product in connection with the activities permitted under the establishment’s LTO.
A CPR should not be treated as a general business license.
It is tied to a particular product and its approved or registered particulars. This means that businesses must pay attention to details such as:
Changes to important product information may require an amendment, variation, or another regulatory application rather than simply changing the product after registration.
The requirement depends on the product category and the FDA rules governing that category.
The FDA’s current eServices platform identifies CPR applications for several categories, including drug products and food products. The system provides separate application pathways for initial registration, renewal, amendment, and, where applicable, reapplication.
Other FDA-regulated products use different authorization mechanisms.
For example:
The FDA’s Citizen Charter for the Center for Device Regulation, Radiation Health, and Research, for example, separately identifies CMDR applications for medical devices and CPR applications for in-vitro diagnostic devices and reagents.
Therefore, before beginning an application, a business should identify exactly what product it intends to sell and determine which FDA authorization applies.
Product classification is one of the most important preliminary steps.
A business should not assume that a product requires a CPR simply because it is regulated by the FDA. Different regulatory frameworks apply depending on whether the product is food, a drug, a cosmetic, a medical device, a household hazardous substance, or another regulated product.
Classification can affect:
This is particularly important for products positioned close to the boundaries between categories.
For example, a product marketed as a food supplement should not automatically be treated as a pharmaceutical product. Similarly, a cosmetic product should not be marketed using drug-like therapeutic claims simply because those claims appear in promotional material.
The FDA has specific rules governing product claims and labeling. Businesses should determine the correct category before investing in packaging, advertising, or large-scale production.
Product registration and establishment licensing are connected.
For businesses applying for food CPRs, FDA materials indicate that the establishment must first secure the appropriate LTO. FDA guidance has stated that food business operators apply for the initial LTO first and file the initial CPR application after the LTO has been approved.
This illustrates an important principle: a product authorization does not replace the establishment’s FDA license.
Depending on the business, the establishment may need to be licensed as a:
The exact category depends on the business activity and product.
Before filing a product application, entrepreneurs should therefore establish the company’s regulatory structure and determine whether its existing LTO covers the activity it intends to conduct.
FDA product registration is only one part of establishing a regulated business in the Philippines.
The company or business should first have the appropriate legal registration. A sole proprietorship generally uses DTI business name registration where applicable, while corporations and partnerships are registered with the Securities and Exchange Commission (SEC).
The business will also generally need to address:
Business registration establishes the legal and administrative foundation of the enterprise. FDA product registration addresses whether a particular regulated product may be marketed or otherwise handled under the applicable FDA rules.
Keeping these two levels separate helps prevent a common mistake: assuming that an SEC certificate or DTI business name registration gives a business authority to sell an FDA-regulated product.
Once the product category and establishment requirements have been identified, the next step is to prepare the supporting documentation.
The exact requirements vary substantially between food, drugs, household hazardous substances, and other product categories. Businesses should therefore use the current checklist issued by the FDA center responsible for the product.
Depending on the category, documentation can address areas such as:
For food products, the FDA’s food registration materials identify specific documentary requirements under the applicable food-registration framework. The FDA’s current Citizen Charter also identifies separate procedures for initial, renewal, amendment, and reapplication of food CPRs.
For pharmaceutical products, the documentation is generally more technical because the FDA evaluates the product under the applicable drug-registration requirements.
Product labeling is an important part of FDA registration.
The label submitted to the FDA should correspond to the product being registered and comply with the applicable labeling rules. Businesses should avoid designing packaging first and attempting to adjust the regulatory information later.
Depending on the product, labeling may need to include information such as:
The exact requirements vary by product category.
Food businesses, for example, must comply with the applicable food labeling requirements, while drug products have substantially different labeling requirements. A cosmetic product also has a different regulatory framework from a pharmaceutical product.
Claims deserve particular attention. Businesses should not make therapeutic, curative, or other regulated claims without the required supporting basis and FDA authorization.
The FDA’s proposed updated food-registration rules specifically state that unsupported therapeutic or scientific claims should not be made on food labels and that food supplements should not carry curative or therapeutic claims.
The FDA has developed electronic systems for many regulatory applications.
The current FDA eServices portal provides dedicated product registration pathways. For food products, for example, the system allows users to initiate applications for:
The FDA’s drug registration system similarly provides application pathways for different categories of human drugs and other pharmaceutical products.
Businesses should use the FDA system and procedure applicable to the product rather than relying on older instructions from previous portal versions.
This is particularly important because the FDA has transitioned several regulatory processes to updated electronic systems. For example, the FDA announced that initial CMDN applications for Class A medical devices moved to the eServices Portal System beginning March 10, 2025.
The application should contain information that is consistent with the company’s LTO and supporting documents.
Product registration involves government fees that vary according to the product, application type, and applicable FDA fee schedule.
The FDA issued Administrative Order No. 2024-0016 establishing updated fees and charges for various FDA regulatory services. The applicable amount should be checked against the current fee schedule and the specific application being filed.
Businesses should distinguish between:
For example, the current FDA fee schedule identifies different CPR fees for household/urban pesticides and other regulated products. It also separately identifies fees for cosmetic product notification, which demonstrates why businesses should not assume that one universal CPR fee applies to every FDA-regulated product.
The business should confirm the applicable fee before payment because fee schedules and regulatory procedures can change.
After submission, the FDA evaluates the application according to the requirements applicable to the product.
The extent of evaluation depends on the product category and its risk profile.
The FDA may examine information relating to:
The objective is not simply to confirm that a form has been submitted. The product must satisfy the applicable regulatory standards.
For pharmaceutical products, the FDA’s regulatory framework expressly provides for review of registration applications for marketing authorization and related authorizations. Administrative Order No. 2024-0013, which became effective in December 2024, established revised rules for registration of pharmaceutical products and active pharmaceutical ingredients intended for human use.
Businesses applying for drug registration should therefore use the current pharmaceutical framework rather than older CPR guides.
An FDA application may not always be approved immediately.
The agency may identify missing documents, inconsistencies, technical deficiencies, or other issues that need to be addressed.
A business should therefore monitor the application and respond within the applicable period when the FDA requests additional information or compliance.
This makes document organization important.
Companies should retain copies of:
Maintaining a regulatory file for every registered product can make future renewals and amendments substantially easier.
A CPR should not be treated as permission to conduct every activity involving the product.
The authorization is connected to the registered product and the establishment activities allowed under the applicable LTO.
For pharmaceutical products, the FDA specifically explains that a CPR or marketing authorization covering a health product is evidence of marketing authority in connection with the activities permitted under the establishment’s LTO.
This distinction matters for businesses that operate across multiple activities.
For example, a company may have a CPR for a particular product but still need to ensure that its establishment is properly licensed for the actual importation, distribution, manufacturing, or other activity it conducts.
Similarly, registering one product does not automatically register every other product owned by the same company.
Businesses with multiple products should not assume that one CPR covers their entire product line.
The FDA’s food-registration framework, for example, contains specific rules concerning when multiple packaging sizes may be covered under one CPR. The same brand, product or variant, formulation, relevant label information, and manufacturer/manufacturing site are among the conditions identified in FDA guidance.
This means a business should evaluate product variations before submitting an application.
Changes involving:
may affect the registration and could require an amendment or a new application.
Businesses should not make material changes to a registered product and assume that the original CPR automatically remains sufficient.
The FDA product registration system is not limited to initial applications.
The FDA’s food eServices system currently provides separate options for initial applications, renewals, amendments, reapplications, corrections, and cancellations.
Each serves a different purpose.
Initial registration is used when a product is being registered for the first time under the applicable procedure.
Renewal is used to maintain an existing registration after its validity period has expired.
An amendment or variation addresses permitted changes to an existing registered product or its information.
Reapplication may be available when an earlier application was disapproved or otherwise falls within the applicable reapplication rules.
The correct application type should be selected based on the actual status of the product.
Obtaining an FDA Certificate of Product Registration does not end the company’s regulatory responsibilities.
Businesses remain responsible for maintaining compliance with applicable requirements.
This can include:
For pharmaceutical products, post-market responsibilities can be particularly significant because the FDA regulates products throughout their market life, not simply at the time of initial registration.
The company should therefore establish an internal regulatory calendar rather than treating FDA registration as a one-time filing.
Food is one of the major areas where CPR requirements apply, but the business must first determine whether the particular food product falls within the FDA registration framework.
The FDA’s current food materials continue to identify requirements for registration of processed food products and provide procedures for initial, renewal, amendment, and reapplication applications.
For food businesses, preparation should cover both the establishment and the product.
This can include:
The company should also review whether its product falls into a category subject to a different FDA treatment.
Pharmaceutical product registration requires a more technical regulatory approach.
The FDA’s Administrative Order No. 2024-0013 established revised rules for pharmaceutical products and active pharmaceutical ingredients intended for human use. The order became effective on December 11, 2024. Existing CPRs issued under the previous rules remain valid until expiration, while renewals and variations are governed by the new framework.
The FDA eServices system currently separates drug applications into categories such as prescription human drugs, over-the-counter and other specified products, vaccines and biologics, and related product categories.
Companies entering the pharmaceutical sector should therefore expect substantially more technical documentation and regulatory review than would apply to a simple business registration.
One of the most important points for entrepreneurs is that FDA authorization terminology varies by product.
The source article that inspired this guide presents CPR as a common requirement across pharmaceuticals, food, cosmetics, and medical devices. However, current FDA systems show that this is too broad a description.
For example, the FDA currently uses Certificate of Product Notification (CPN) for cosmetics. The FDA has also issued recent advisories identifying cosmetics without the required CPN as unauthorized products.
For medical devices, the FDA distinguishes between CMDN and CMDR according to device classification. The agency announced that Class A devices require CMDN, while Class B, C, and D devices require CMDR under the applicable framework.
This distinction should be established before a company begins preparing its regulatory application.
An FDA Certificate of Product Registration is an important product-level authorization for applicable regulated products in the Philippines. However, it should not be confused with an FDA License to Operate or treated as the authorization used for every FDA-regulated product.
The FDA’s current systems distinguish among different product authorizations. Food and drug products have CPR pathways, while cosmetics generally use product notification, and medical devices use CMDN or CMDR, depending on classification.
Businesses should therefore begin with product classification before preparing documents or paying application fees. The appropriate FDA center, establishment LTO, product authorization, technical documents, labeling requirements, and post-registration obligations can then be identified.
For companies entering regulated industries, the most practical approach is to coordinate FDA requirements with the wider Philippine business registration process. This helps ensure that the business entity, establishment, product, labels, and regulatory documents provide consistent information and that the required authorizations are addressed before commercial operations begin.
FDA product registration can involve technical documents, product classification, establishment licensing, labeling requirements, regulatory applications, and continuing compliance. Businesses may also need to coordinate FDA requirements with their DTI or SEC registration, BIR registration, local permits, and other regulatory obligations.
BusinessRegistrationPhilippines.com can assist entrepreneurs and investors in understanding the Philippine business registration framework and coordinating the requirements associated with establishing a compliant business: